Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAmg universal flu vaccine
- Development stage
- Preclinical
- Lead developer
- RuenHuei
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
HAmg universal flu vaccine is a monoglycosylated recombinant hemagglutinin (HA) protein vaccine candidate in preclinical development by RuenHuei Biopharmaceuticals (RH Biopharma) in collaboration with OPKO Health, under a license from Academia Sinica. The vaccine is designed to elicit broad, cross-strain protective immunity against various influenza strains, including H1N1. By enzymatically trimming the N-glycans on the hemagglutinin protein to leave only a single N-linked N-acetylglucosamine (GlcNAc) residue at each glycosylation site, the vaccine exposes highly conserved epitopes (such as the HA stem region) that are normally shielded by the glycan coat. This glycoengineering approach enhances the immunogenicity of the conserved regions of HA, promoting the production of broadly neutralizing antibodies and providing superior cross-strain protection compared to fully glycosylated seasonal influenza vaccines.
- Other names
- monoglycosylated HAmonoglycosylated hemagglutininUniversal Flu Vaccine Platform
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on HAmg universal flu vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAmg universal flu vaccine.